CRBP - Company ID 0001595097
The table below shows Corbus Pharmaceuticals Holdings, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$25.57M | -$16.42M | -$7.97M | -$15.11M | -$10.62M | -$21.81M |
| Capital expenditure | $6.00K | $0.00 | - | $0.00 | $13.45K | - |
| Investing cash flow | $22.45M | $18.12M | -$98.24M | $5.55M | $42.96M | -$57.42M |
| Dividends paid | - | - | - | - |
Corbus Pharmaceuticals Holdings, Inc. reported operating cash flow of -$64.49M for fiscal year 2025. That is down 54.3% from -$41.79M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$27.80M (FY 2017) to -$64.49M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | - | $0.00 | $106.58M | -$113.01K | -$327.13K | $60.41M |